| CYP2C9 Genetic Polymorphism is a Potential Predictive Marker for the Efficacy of Rosuvastatin Therapy | |
| Lin, Jiayao; Zhang, Yu; Zhou, Houguang; Wang, Xinqing; Wang, Wenwen | |
| 刊名 | CLINICAL LABORATORY
 |
| 2015 | |
| 卷号 | 61期号:9 |
| 关键词 | CYP2C9 polymorphism rosuvastatin hyperlipidemia efficacy tolerability |
| ISSN号 | 1433-6510 |
| URL标识 | 查看原文 |
| 语种 | 英语 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/4869400 |
| 专题 | 复旦大学上海医学院 |
| 推荐引用方式 GB/T 7714 | Lin, Jiayao,Zhang, Yu,Zhou, Houguang,et al. CYP2C9 Genetic Polymorphism is a Potential Predictive Marker for the Efficacy of Rosuvastatin Therapy[J]. CLINICAL LABORATORY,2015,61(9). |
| APA | Lin, Jiayao,Zhang, Yu,Zhou, Houguang,Wang, Xinqing,&Wang, Wenwen.(2015).CYP2C9 Genetic Polymorphism is a Potential Predictive Marker for the Efficacy of Rosuvastatin Therapy.CLINICAL LABORATORY,61(9). |
| MLA | Lin, Jiayao,et al."CYP2C9 Genetic Polymorphism is a Potential Predictive Marker for the Efficacy of Rosuvastatin Therapy".CLINICAL LABORATORY 61.9(2015). |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论